UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
December 5, 2019
Date of Report (Date of earliest event reported)
AEVI
GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction
of
incorporation or organization)
|
(Commission File
Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park
Drive, Suite 715
Wayne, Pennsylvania
19087
(Address of principal
executive offices, zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name
of exchange on which registered
|
Common stock, par
value $0.0001 per share
|
GNMX
|
Nasdaq Capital Market
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
x
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01.
|
Entry Into a
Material Definitive Agreement.
|
Agreement
and Plan of Merger
On December
5, 2019, Aevi Genomic Medicine, Inc., a Delaware corporation (“Aevi”), entered into an Agreement and Plan
of Merger and Reorganization (the “Merger Agreement”) with Cerecor, Inc., a Delaware corporation
(“Cerecor”), Genie Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Cerecor
(“Merger Sub”), and Second Genie Merger Sub, LLC, a Delaware limited liability company and a wholly owned
subsidiary of Cerecor (“Second Merger Sub”), pursuant to which Merger Sub shall merge with and into Aevi (the
“First Merger”) and as part of the same overall transaction, Aevi shall then merge with and into the Second
Merger Sub (the “Second Merger” and together with the First Merger, the “Mergers”), with the Second
Merger Sub as the surviving corporation. Following closing, the combined bio-pharmaceutical company will continue to be
focused on pediatric orphan diseases and will operate under the name Cerecor. Michael F. Cola will become the Chief Executive
Officer and Garry Neil will become the Chief Medical Officer of the combined company.
The
boards of directors of both Aevi and Cerecor have approved the proposed Mergers. The consummation of each of the Mergers is subject
to customary closing conditions, including the stockholders of Aevi approving the Mergers and the Securities and Exchange Commission
declaring effective the registration statement on which the shares of Cerecor common stock issued in the Mergers will be registered.
The Mergers are expected to close during the first quarter of 2020.
Upon completion
of the Mergers, each share of Aevi common stock that is outstanding immediately prior to the effective time of the Mergers
(other than cancelled shares or dissenting shares), inclusive of common stock issued upon conversion of convertible notes
issued by Aevi, will automatically be converted into the right to receive (A) the fraction of a share of Cerecor common stock
equal to the exchange ratio set forth in the Merger Agreement and summarized below, (B) one contingent value right (a
“CVR”), which shall represent the right to receive contingent payments upon the achievement of certain milestones
(the “CVR Consideration”) as set forth in the CVR Agreement (as defined and described below), and (C) cash in
lieu of fractional shares of Cerecor common stock as contemplated in the Merger Agreement. Cerecor will acquire all
outstanding shares of Aevi common stock at an aggregate purchase price of $16.1 million less an amount by which Aevi’s
net assets at closing are less than negative $1.3 million, but in no event will such adjustment be more than $500,000. The
per share price will be based on the number of Aevi shares outstanding immediately prior to closing, including the shares of
Aevi stock to be issued to The Children’s Hospital of Philadelphia upon conversion of its outstanding secured
promissory note and to AstraZeneca in connection with the exercise by Aevi of its license option for MEDI2338, which is
anticipated to result in an approximate per share value of $0.134, assuming the maximum net asset related
adjustment, excluding any potential payment in connection with the CVRs. The purchase price will be paid in Cerecor common stock
valued based on an average of the volume weighted price of Cerecor common stock 20 days prior to signing and closing.
The
Merger Agreement contains customary representations and warranties of Aevi, Cerecor, Merger Sub and Second Merger Sub, and customary
pre-closing covenants, including covenants requiring Aevi (i) to use reasonable best efforts to cause the consummation of
the transactions contemplated by the Merger Agreement, (ii) to conduct its business in the ordinary course, and (iii) to
refrain from taking certain actions without Cerecor’s consent.
The Merger Agreement
also includes customary provisions prohibiting any solicitation or negotiations by Aevi of other possible acquisition transactions
or any adverse change to the Aevi board of directors’ recommendation to approve the Mergers. Aevi may provide information
to, and engage in, negotiations with a potential acquirer prior to obtaining stockholder approval for the Mergers if the Aevi board
of directors: (a) determines in good faith after consultation that the unsolicited offer is bona fide and constitutes a superior
proposal to Cerecor’s offer; (b) thereafter furnish to such potential acquirer non-public information relating to Aevi or
any of its subsidiaries pursuant to an executed confidentiality and standstill agreement that contains confidentiality and standstill
provisions that are no less favorable to Aevi than those contained in the confidentiality agreement between Cerecor and Aevi;
(c) following receipt of and on account of a superior proposal, make a “Company Adverse Recommendation Change” (as
defined in the Merger Agreement); and (d) take any action that any court of competent jurisdiction orders Aevi to take. The Aevi
board of directors may also, prior to obtaining stockholder approval for the Mergers, make a Company Adverse Recommendation Change
or terminate the Merger Agreement and enter into a different acquisition agreement in order to accept another takeover proposal
that the Board determines in good faith is more favorable from a financial point of view to Aevi’s stockholders and is reasonably
likely to be consummated.
The Merger Agreement
contains customary termination rights and may be terminated by either Cerecor or Aevi at any time prior to the effective time
of the Mergers if: (a) the parties mutually consent to do so; (b) the Mergers have not been consummated on or before
April 30, 2020 (the “End Date”) (or, for Cerecor only, 90 business days following such date if the Form S-4 referenced
below has not been declared effective as of the End Date); (c) if any governmental entity of competent jurisdiction shall have
enacted, issued, promulgated, enforced, or entered any law or order making illegal, permanently enjoining, or otherwise permanently
prohibiting the consummation of the Mergers or the other transactions contemplated by the Merger Agreement; or (d) the Merger
Agreement has been submitted to the stockholders of Aevi for adoption at a duly convened stockholders meeting and the requisite
vote shall not have been obtained at such meeting.
Cerecor may terminate
the Merger Agreement if it is not then in material breach of its representations, warranties, covenants and obligations in the
Merger Agreement and if: (i) a Company Adverse Recommendation Change has occurred; (ii) Aevi intentionally and materially breaches
or fails to perform any of its obligations related to non-solicitation of takeover proposals and any Company Adverse Recommendation
Change; or (iii) there is any breach of any representation, warranty, covenant, or agreement on the part of Aevi set forth in
the Merger Agreement such that the conditions to the closing of the Mergers regarding: (A) Aevi’s representations and warranties;
or (B) Aevi’s performance of Aevi’s pre-closing covenants, would not be satisfied and such breach is not capable of
being cured, or is not cured, by the End Date; provided, however, that Cerecor shall give Aevi at least 30 days written notice
prior to such termination. If Cerecor terminates the Merger Agreement in accordance with (i) or (ii) above, and at the time or
prior to such termination Aevi has entered into another transaction with respect to a Superior Proposal, then, upon completion
of such transaction, Aevi shall pay to Cerecor an amount equal to $600,000 (the “Termination Fee”).
Aevi may terminate
the Merger Agreement if it is not then in material breach of the Merger Agreement and if: (i) prior to receiving stockholder approval
of the Mergers, in accordance with the terms of the Merger Agreement, its board of directors approves or recommends, or Aevi executes,
a definitive agreement with respect to a Superior Proposal; (ii) prior to receiving stockholder approval of the Mergers, in accordance
with the terms of the Merger Agreement, the Board otherwise effects a Company Adverse Recommendation Change; or (iii) there is
any breach of any representation, warranty, covenant, or agreement on the part of Cerecor, Merger Sub or Second Merger Sub set
forth in the Merger Agreement such that the conditions to the closing of the Mergers regarding (A) Cerecor’s, Merger Sub’s
and Second Merger Sub’s representations and warranties, or (B) Cerecor’s, Merger Sub’s and Second Merger Sub’s
performance of their pre-closing covenants, would not be satisfied and such breach is not capable of being cured, or is not cured,
by the End Date; provided, however, that Aevi shall give Cerecor at least 30 days written notice prior to such termination. The
Termination Fee would be payable by Aevi if Aevi terminates the Merger Agreement in accordance with (i) above and Aevi has completed
a transaction in connection with therewith that was the cause of the termination.
The
foregoing summary of the Merger Agreement is qualified in its entirety by reference to the complete text of such document, which
is filed as Exhibit 2.1 attached hereto and which is incorporated herein by reference.
Form
of Voting Agreement
In
connection with entering into the Merger Agreement, certain stockholders of Aevi have entered into a voting agreement with Cerecor
(the “Voting Agreement”) as a condition and inducement to the willingness of Cerecor, Merger Sub and Second Merger
Sub to enter into the Merger Agreement. Parties to the Voting Agreement include The Children’s Hospital of Philadelphia
and certain directors and officers of Aevi. The foregoing summary of the Voting Agreement is qualified in its entirety by reference
to the complete text of such document, a form of which is filed as Exhibit 10.1 attached hereto and which is incorporated herein
by reference.
Form
of CVR Agreement
The
CVR Agreement provides the terms and conditions upon which each holder of a CVR shall be entitled to receive the CVR Consideration.
The CVR Consideration is an amount up to $6,500,000 ($2,000,000 upon enrollment of first patient in a Phase II clinical trial
for AEVI-002, AEVI-006 or AEVI-007 within 24 months of closing, and $4,500,000 upon NDA approval for AEVI-006 or AEVI-007 within
60 months of closing) divided by the total number of shares of Aevi common stock issued and outstanding immediately prior to the
time the Mergers becomes effective. The CVR Consideration will be paid in cash or stock, at Cerecor’s sole discretion.
The
foregoing summary of the CVR Agreement is qualified in its entirety by reference to the complete text of such document, a form
of which is contained as an exhibit to the Merger Agreement which is filed as Exhibit 2.1 attached hereto and which is incorporated
herein by reference.
Notes
In
connection with the Merger Agreement, Cerecor agreed to fund certain of Aevi’s expenses related to the exercise of its option
to license certain intellection property assets, as well as to fund the operating expenses of Aevi through the earlier of the
termination of the Merger Agreement or the closing of the Mergers, pursuant to the terms of two promissory notes in consideration
for the loans for such expenses (the “Notes”).
The
foregoing summary of the Notes is qualified in its entirety by reference to the complete text of such Notes, which are filed as
Exhibits 10.2 and 10.3 attached hereto and which are incorporated herein by reference.
Additional
Information about the Mergers and Where to Find It
This
document does not constitute an offer to sell or the solicitation of an offer to buy any securities of Aevi or Cerecor or the
solicitation of any vote or approval. In connection with the proposed Mergers, Cerecor will file with the SEC a Registration Statement
on Form S-4 containing a proxy statement/prospectus. The proxy statement/prospectus will contain important information about Aevi,
Cerecor, the Mergers and related matters. Aevi will mail or otherwise deliver the proxy statement/prospectus to its stockholders
when it becomes available. Investors and security holders of Aevi and Cerecor are urged to read carefully the proxy statement/prospectus
relating to the Mergers (including any amendments or supplements thereto) in its entirety when it is available, because it will
contain important information about the proposed Mergers.
Investors
and security holders of Aevi and Cerecor will be able to obtain free copies of the proxy statement/prospectus for the proposed
Mergers (when it is available) and other documents filed with the SEC by Aevi and Cerecor through the website maintained by the
SEC at www.sec.gov. In addition, investors and security holders of Aevi will be able to obtain free copies of the proxy statement/prospectus
for the proposed Mergers (when it is available) by contacting Aevi, Attn: Mike McInaw, michael.mcinaw@aevigenomics.com.
Investors and security holders of Cerecor will be able to obtain free copies of the proxy statement/prospectus for the merger
by contacting Cerecor, Attn: James Harrell, jharrell@cerecor.com.
Participants
in the Mergers
Aevi,
Cerecor and certain of their respective directors and executive officers may be deemed to be participants in the solicitation
of proxies from the stockholders of Aevi in respect of the transactions contemplated by the Merger Agreement between Aevi and
Cerecor. Information regarding Aevi’s directors and executive officers is contained in Aevi’s Annual Report on Form
10-K for the fiscal year ended December 31, 2018, which was filed with the SEC on March 29, 2019, and will also be available in
the proxy statement/prospectus that will be filed by Cerecor with the SEC in connection with the proposed Mergers. Information
regarding Cerecor’s directors and executive officers is contained in Cerecor’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2018, which was filed with the SEC on March 18, 2019, and will also be available in the proxy statement/prospectus
that will be filed by Cerecor with the SEC in connection with the proposed Mergers.
Cautionary
Statement Regarding Forward-Looking Statements
This
document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, including,
but not limited to, Aevi’s and Cerecor’s expectations or predictions of future financial or business performance or
conditions. Forward-looking statements are sometimes identified by their use of the terms and phrases such as “estimate,”
“project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,
“expect,” “believe,” “will,” “will likely,” “should,” “could,”
“would,” “may” or the negative of such terms and other comparable terminology. These forward-looking statements
are subject to numerous assumptions, risks and uncertainties, which change over time, are difficult to predict and are generally
beyond the control of either company. Actual results may differ materially from current projections.
Important
factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical
experience include risks and uncertainties, including the timing and completion of the Mergers, the parties’ ability to
satisfy the closing conditions of the Merger Agreement, the failure by Aevi or Cerecor to secure and maintain relationships with
collaborators and/or investors; risks relating to clinical trials; risks relating to the commercialization, if any, of Aevi’s
or Cerecor’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other
risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that Aevi or Cerecor may lack
the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could
affect Aevi’s and Cerecor’s respective businesses, financial conditions and results of operations are contained in
Aevi’s and Cerecor’s filings with the U.S. Securities and Exchange Commission, or SEC, which are available at www.sec.gov.
The forward-looking statements represent Aevi’s and Cerecor’s estimate as of the date hereof only, and Aevi and Cerecor
specifically disclaim any duty or obligation to update forward-looking statements.
On December 5, 2019,
Aevi issued a press release announcing the execution of the Merger Agreement. The press release is attached as Exhibit 99.1 and
is incorporated by reference herein.
Item 9.01.
|
Financial Statements
and Exhibits.
|
(d) Exhibits.
Exhibit
No.
|
Description
|
2.1*
|
Agreement
and Plan of Merger and Reorganization, dated as of December 5, 2019 among Aevi Genomic Medicine, Inc., Genie Merger Sub, Inc., Second
Genie Merger Sub, LLC and Cerecor Inc. (including the Form of Contingent Value Rights Agreement)
|
10.1
|
Form
of Voting Agreement of Aevi Genomic Medicine, Inc. dated December 5, 2019
|
10.2
|
Promissory
Note for License Expenses, dated December 5, 2019, by and between Cerecor Inc. and Aevi Genomic Medicine, Inc.
|
10.3
|
Promissory
Note for Operating Expenses, dated December 5, 2019, by and between Cerecor Inc. and Aevi Genomic Medicine, Inc.
|
99.1
|
Press
Release issued by Aevi Genomic Medicine, Inc. dated December 5, 2019
|
*
|
The schedules
and exhibits to the Agreement and Plan of Merger have been omitted from this filing pursuant to Item 601(b)(2) of Regulation
S-K. Aevi will furnish copies of any such schedules or exhibits to the SEC upon request.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
By:
|
/s/
Michael F. Cola
|
|
|
Name: Michael F. Cola
|
|
|
Title: President and Chief Executive Officer
|
Date: December 5, 2019
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2023 to Sep 2024